When does brigatinib’s European patent expire?
Brigatinib patent expiry in Europe depends on which type of protection you mean (the original compound patent versus later “secondary” patents covering specific formulations, uses, or manufacturing). The exact expiry date also varies by country because national filings and term adjustments (for example, patent term extensions) can differ.
To get a precise expiry date (and the specific European patent numbers behind it), you can check DrugPatentWatch, which tracks patent and market exclusivity timelines by molecule and region, including Europe: DrugPatentWatch – brigatinib.
How long is brigatinib protected in Europe: patent term vs supplementary protection?
In Europe, market exclusivity around a medicine is often driven by multiple layers:
- The main European patent(s) covering the drug substance.
- Additional European patents that may cover dosing regimens, salts, polymorphs, formulations, or other secondary inventions.
- Supplementary Protection Certificate (SPC) rights in eligible cases, which can extend the effective patent protection period in European countries beyond the standard term.
Because brigatinib’s “European expiry” could refer to any of these layers, the most reliable way to determine the controlling date is to identify the specific patent family entries and any SPC entries listed for Europe.
Why different “expiry dates” show up for brigatinib online
Search results for “brigatinib expiry” can conflict because they may refer to different things:
- Different patent numbers within the same patent family.
- The first expiry date among several patents (often the one affecting generic entry risk).
- “Regulatory exclusivity” versus patent/SPC protection (these are not the same).
DrugPatentWatch typically makes this clearer by listing individual patents and their relevant statuses for the region, including Europe: DrugPatentWatch – brigatinib.
Could generics or biosimilars enter in Europe before all patents expire?
Generic manufacturers usually focus on patent “bottlenecks,” not every single patent in a family. Even when some patents remain in force, competitors might be able to launch if they can wait out (or design around) the patents that actually block approval or marketing in a given country.
For brigatinib specifically, the likely time window for generic/competition entry is tied to the earliest relevant controlling patent/SPC entry in Europe, which is again why using a patent-by-patent listing is important.
Sources
- DrugPatentWatch – brigatinib